Thurston Springer Miller Herd & Titak Inc. Purchases Shares of 2,736 Envista Holdings Co. (NYSE:NVST)

Thurston Springer Miller Herd & Titak Inc. purchased a new stake in Envista Holdings Co. (NYSE:NVST) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 2,736 shares of the company’s stock, valued at approximately $53,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. acquired a new position in Envista during the third quarter worth approximately $31,000. GAMMA Investing LLC increased its position in Envista by 69.8% during the third quarter. GAMMA Investing LLC now owns 1,766 shares of the company’s stock worth $35,000 after buying an additional 726 shares during the last quarter. Huntington National Bank increased its position in Envista by 97.8% during the third quarter. Huntington National Bank now owns 1,919 shares of the company’s stock worth $38,000 after buying an additional 949 shares during the last quarter. Blue Trust Inc. increased its position in Envista by 69.7% during the third quarter. Blue Trust Inc. now owns 1,957 shares of the company’s stock worth $39,000 after buying an additional 804 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC increased its position in Envista by 50.8% during the third quarter. Allspring Global Investments Holdings LLC now owns 2,161 shares of the company’s stock worth $43,000 after buying an additional 728 shares during the last quarter.

Analysts Set New Price Targets

A number of brokerages have weighed in on NVST. Leerink Partnrs raised Envista from a “strong sell” rating to a “hold” rating in a research report on Thursday, October 31st. Stifel Nicolaus boosted their price target on Envista from $18.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, October 23rd. Evercore ISI boosted their price objective on Envista from $18.00 to $23.00 and gave the stock an “outperform” rating in a report on Monday, September 23rd. Mizuho started coverage on Envista in a report on Wednesday, December 4th. They set an “underperform” rating and a $20.00 price objective for the company. Finally, Piper Sandler boosted their price objective on Envista from $16.00 to $17.00 and gave the stock a “neutral” rating in a report on Thursday, October 31st. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $20.21.

Envista Stock Up 3.3 %

Shares of NVST opened at $19.83 on Friday. Envista Holdings Co. has a one year low of $15.15 and a one year high of $24.79. The company has a market cap of $3.41 billion, a P/E ratio of -2.55, a P/E/G ratio of 1.66 and a beta of 1.33. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.08 and a quick ratio of 1.77. The firm has a 50 day simple moving average of $20.00 and a two-hundred day simple moving average of $18.68.

Envista (NYSE:NVST) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $0.12 EPS for the quarter, beating the consensus estimate of $0.09 by $0.03. Envista had a negative net margin of 53.42% and a positive return on equity of 3.76%. The business had revenue of $601.00 million during the quarter, compared to the consensus estimate of $590.34 million. During the same period in the previous year, the business earned $0.43 earnings per share. The company’s revenue was down 4.8% on a year-over-year basis. Research analysts forecast that Envista Holdings Co. will post 0.72 EPS for the current fiscal year.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.